{"prompt": "['Carbomer and Carboxymethylcellulose', '209510', 'Clinical Protocol V1.0', '6.3', 'Investigational/Study Product Storage', 'The investigator, or designee, will ensure that all study products are stored in a secured area', 'with controlled access under required storage conditions and in accordance with applicable', 'regulatory requirements and the product label.', 'Site systems must be capable of measuring and documenting (for example, via a log), at a', 'minimum, daily minimum and maximum temperatures for all site storage locations (as', 'applicable, including frozen, refrigerated, and/or room-temperature products). This should be', 'captured from the time of first product receipt throughout the study. Even for continuous', 'monitoring systems, a log or site procedure that ensures active daily evaluation for excursions', 'should be available. The operation of the temperature-monitoring device and storage unit (for', 'example, refrigerator), as applicable, should be regularly inspected to ensure it is maintained in', 'working order.', 'Any excursions from the product-label storage conditions should be reported to appropriate site', 'staff upon discovery and communicated to Sponsor as soon as possible. The site should actively', 'pursue options for returning the product to the storage conditions as described in the labeling,', 'as soon as possible. Excursions from the storage requirements, including any actions taken,', 'must be documented as a protocol deviation and reported to the Sponsor.', 'Once an excursion is identified, the affected product (or products) must be quarantined and not', 'used until the Sponsor provides documentation of permission to use. Use of any of the affected', 'product(s) prior to Sponsor approval will be considered a protocol deviation.', 'Site staff will instruct subjects on the proper storage requirements for all take-home products.', '6.4', 'Investigational/Study Product Accountability', 'All products supplied are for use only in this clinical study and should not be used for any other', 'purpose.', 'All study products must be received by a designated person at the study sites, handled and stored', 'safely and properly, and kept in a secured location to which only the staff have access. Upon', 'receipt, all study products should be stored according to the instructions specified on the product', 'labels. Study products are to be dispensed only to subjects enrolled in the study in accordance', 'with the protocol, by authorized site staff.', 'The investigative site must maintain adequate records documenting the receipt, use, loss, or', 'other disposition of all the product supplies. All study products will be accounted for using the', 'investigational/study product accountability form/record. The investigator is responsible for', 'study product accountability, reconciliation, and record maintenance.', 'The accountability records must be available for inspection by the study monitor during the', 'study. Monitoring of product accountability will be performed by the monitor during site visits', 'and at the completion of the study.', 'All unused product should be returned to the study site by the subjects at each visit.', '6.4.1', 'Destruction of Investigational/Study Product Supplies', 'At the conclusion of the study, the Principal Investigator or an appropriate designee, and a', 'representative of GSK CH (study monitor) will inventory all used and unused study products', 'and sundry items. The investigational/study product accountability record for returned study', 'products will then be completed. All study product (used and unused) for this clinical study will', 'be returned for destruction to the GSK CH Clinical Supplies Department or designated vendor', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 24 of 65']['Carbomer and Carboxymethylcellulose', '209510', 'Clinical Protocol V1.0', 'using the return instructions provided. Used denture brushes, denture cleansing paste and', 'pregnancy test kits should be disposed of in accordance with the site disposal procedures.', '6.5', 'Blinding and Allocation/Randomization', 'All subjects will be centrally randomized to one of the study arms using an Interactive Response', 'Technology (IRT). Before the study is initiated, training, login information and directions for', 'the IRT will be provided to each site. Study products will be dispensed according to the', 'instruction received through the IRT at the appropriate study visits.', \"The investigator's knowledge of the product allocation should not influence the decision to\", 'enroll a particular subject or affect the order in which subjects are enrolled.', 'This study is described as single-blind (the safety assessor and the examiner determining the', 'denture-bearing tissue score clinical examiner will be blinded to the product received). The', 'study statistician, data management staff, other employees of the Sponsor and vendors acting', 'on behalf of the Sponsor, who may influence study outcomes will also be blinded to the product', 'allocation.', 'To ensure the examiner remains blinded throughout the study, staff involved in the dispensing', 'of study products will work in a separate area. The examiner is not permitted in any area where', 'study product is stored, dispensed, or in use.', 'Subjects will be instructed not to remove study products from the opaque bags provided outside', 'of the dispensing room, while at the study site. Subjects randomized to test adhesive use will', 'have the study test product, the denture cleaning brush and their diary and usage instructions', 'contained within the bag, whilst the subjects randomized to no adhesive usage will have their', 'diary in the bag.', 'Dispensing staff will not be involved in any efficacy/safety assessment procedures during the', 'study.', '6.6', 'Breaking the Blind', 'At the initiation of the study, the study site will be instructed on the method for breaking the', 'blind. The method will be an electronic process.', 'The electronic system will be programmed with blind-breaking instructions. In case of an', 'emergency, the investigator has the sole responsibility for determining if unblinding of a', \"subject's product assignment is warranted. Subject safety must always be the first consideration\", 'in making such a determination. If the investigator decides that unblinding is warranted, the', \"investigator should make every effort to contact the Sponsor prior to unblinding a subject's\", 'product assignment unless this could delay emergency treatment of the subject.', \"If a subject's product assignment is unblinded, the Sponsor must be notified within 24 hours\", 'after breaking the blind. The date and reason that the blind was broken must be recorded in the', 'source documentation and case report form, as applicable.', 'Any AE associated with breaking the blind must be recorded and reported as specified in this', 'protocol. The study site may also be required be required to inform the Institutional Review', 'Board / Ethics Committee (IRB/EC) if the blind is broken.', '6.7', 'Subject Compliance', 'Subjects randomized to the test denture adhesive arm will be instructed in/reminded of the', 'correct usage of the product at every visit by the dispensing staff.', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 25 of 65']\n\n###\n\n", "completion": "END"}